• Praluent® can be injected subcutaneously into the thigh, abdomen or upper arm. Patients should rotate the injection site with each injection.1

    Ease of use assessed as ≥9.8 out of 10 in all assessments for both devices*2

    300 mg Q4W

    75 mg and 150 mg Q2W

    Praluent® pre-filled pen

    Adapted from Roth et al. 2015 and Praluent SmPC.1,6

    All patients agreed that learning to use the PRALUENT pre-filled pen is easy because all the parts are clearly labelled and colour-coded**5

    • Self-injected or caregiver administered1
    • Same device available in two dosing strengths (75 mg and 150 mg)1

    Up to 30 days out of the fridge1

    • Store in a refrigerator (2°C to 8°C). Do not freeze
    • PRALUENT can be kept outside a refrigerator below 25°C and protected from light for a single period not exceeding 30 days
    • After removal from the refrigerator, the medicinal product must be used within 30 days or discarded.

    Although many patients requiring lipid lowering therapies are not experienced with self-injected medication, in a real world study, results indicated that the pre-filled pen was well-accepted by patients.6

    Dosage information

    The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously. The dose of PRALUENT can be individualised based on patient characteristics such as baseline LDL-C level, goal of therapy, and response. Lipid levels can be assessed 4 to 8 weeks after treatment initiation or titration, and dose adjusted accordingly (up-titration or down-titration). If additional LDL-C reduction is needed in patients treated with 75 mg once every 2 weeks or 300 mg once every 4 weeks (monthly), the dosage may be adjusted to the maximum dosage of 150 mg once every 2 weeks. If a dose is missed, the patient should administer the injection as soon as possible and thereafter resume treatment on the original schedule.


    Learn more


    Learn more

    *Study of 69 patients who randomly received unsupervised, self-administered alirocumab 300 mg via 1 x 300 mg injection with the SYDNEY device (n=35) or 2 x 150 mg injections with the currently approved auto-injector (n=34). Possible answers ranged from 1 (very dissatisfied) to 10 (very satisfied).
    **Evaluated in a cross-sectional, non-interventional study involving 151 patients enrolled in Praluent® phase 3 trials.
    SmPC=summary of product characteristics.

    1. Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/8093/smpc. Accessed April 2022.
    2. Frias JP, Koren MJ, Loizeau V, et al. The SYDNEY Device Study: A Multicenter, Randomized, Open-label Usability Study of a 2-mL Alirocumab Autoinjector Device. Clinical Therapeutics. 2020; 42(1):94-107.
    3. Praluent Patient information lealfet 150mg. November 2020.
    4. Praluent Patient information leaflet 300mg. November 2020.
    5. Tatlock S, et al. Value Health 2017;20:430–440.
    6. Roth E, et al. Clin Ther 2015;37(9):1945–1954.